← Search & browse all drugs
MUSCULO-SKELETAL SYSTEM › DRUGS FOR TREATMENT OF BONE DISEASES › DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION › Other drugs affecting bone structure and mineralization
ipriflavone
M05BX01
Forms & Strengths
- Oral capsules: 200 mg
- Oral tablets: 300 mg
Adult Dosing
- Postmenopausal osteoporosis: 600 mg orally daily, divided into three 200 mg doses taken with meals
Pediatric Dosing
- Safety and efficacy not established in pediatric populations
Indications
- Prevention and treatment of postmenopausal osteoporosis
- Reduction of bone turnover markers
Mechanism of Action
- Synthetic isoflavone derivative that inhibits osteoclast-mediated bone resorption
- May stimulate osteoblastic bone formation and calcium incorporation into bone matrix
- Acts independently of estrogen receptors
Contraindications
- Hypersensitivity to ipriflavone or excipients
- Severe renal impairment
- Severe hepatic impairment
- History of lymphocytopenia or severe leukopenia
Adverse Reactions
- Nausea
- Dyspepsia
- Gastric discomfort
- Lymphocytopenia
- Leukopenia
- Elevated serum transaminases
Drug Interactions
- Theophylline: May inhibit CYP1A2 metabolism, leading to increased serum theophylline concentrations and toxicity
- Warfarin: Potential for enhanced anticoagulant effect due to altered metabolism
- Phenytoin: May alter metabolism and clearance of concomitantly administered drugs metabolized by hepatic cytochrome P450 enzymes
Curated Content: Needs Vetting Before Put to Clinical Use